Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 11/20 | 0.65 |
| ▸ | MMP13 | P45452 | 10/20 | 0.65 |
| ▸ | MMP2 | P08253 | 1/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.65 |
| ▸ | MMP14 | P50281 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.50 |
| ▸ | SOX18 | P35713 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802719 | 0.86 | CYP1A2 (0.49) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL6795573 | 0.84 | CYP1A2 (0.53) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL6801159 | 0.84 | CYP1A2 (0.53) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL5320128 | 0.83 | CYP1A2 (0.56) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL8333817 | 0.81 | MMP12 (0.80) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL687094 | 0.81 | MMP12 (0.80) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL4745347 | 0.81 | MMP12 (0.80) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL27862101 | 0.81 | CYP1A2 (0.57) | CYP1A2SLC13A5SOX18PDPK1 | |
| SCHEMBL21443063 | 0.80 | CYP1A2 (0.47) | CYP1A2SLC13A5SOX18PDPK1 | |
| SCHEMBL5613354 | 0.79 | MMP12 (1.00) | MMP12MMP13MMP2MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-0854863-B1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
| EP-0854863-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | MMP12 2293/4885MMP13 1956/4885MMP2 694/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | MMP12 2405/4885MMP13 2083/4885MMP2 686/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | MMP12 2237/4885MMP13 1881/4885MMP2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.